The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2021 | Who should undergo MRD monitoring in myeloma?
The clinical value of measurable residual disease (MRD) in multiple myeloma has become apparent in recent years, with growing data to support its use as a prognostic marker, clinical trial endpoint, and aid for clinical decision making. Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the optimal use of MRD monitoring in myeloma. MRD is a useful measure of depth of response and thus, Dr Paiva believes all patients achieving a negative result by immunofixation should undergo MRD assessment. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
